You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. SBIR Phase I:Advanced multi-locus genome engineering to enable consolidated bioprocessing for the low-cost conversion of lignocellulose to hydrocarbon fuels and products

    SBC: Mascoma Corporation            Topic: BT

    The broader impact of this Small Business Innovation Research (SBIR) Phase I project is to test an innovative new approach to generating industrially valuable microorganisms. If successful, the new approach will be demonstrated by improving the ability of an engineered bacterium to convert components of biomass into fuel. The benefit of that research will be to help develop a technology that can c ...

    SBIR Phase I 2023 National Science Foundation
  2. SBIR Phase I:Comfortable, Easy-to-Insert Hearing Protection Earplug

    SBC: Rapa Technologies LLC            Topic: MD

    The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a novel hearing protection device which reduces the societal cost of noise induced hearing loss. Noise induced hearing loss is the one of the most prevalent occupational injuries in both US industry and the military, affecting more than 10 million workers at a total preventable economic cos ...

    SBIR Phase I 2023 National Science Foundation
  3. SBIR Phase II:Integrated Point-of-Care System for Rapid Pathogen Identification and Characterization

    SBC: NANOPATH INC.            Topic: BM

    The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is improved access to state-of-the-art molecular diagnostic technologies in areas of significant unmet clinical need, such as women’s health. During the NSF I-Corps Program, the team identified urinary tract infections (UTIs) as pressing problem due to the currently lengthy clinical workflo ...

    SBIR Phase II 2023 National Science Foundation
  4. A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome

    SBC: CELDARA MEDICAL, LLC            Topic: NIAID

    PROJECT SUMMARY Rodent-borne viral outbreaks are increasing in both frequency and impact. As weather patterns evolve, rodent populations are affected and may multiply in areas where increased contact with humans results in infection. Hantaviruses, including Andes (ANDV) and Sin Nombre (SNV), are transmitted through the excreta of infected rodents and, when aerosolized, infect humans. In the Americ ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. PARCA (a digital tool) to improve Justice and Health

    SBC: Q2I, LLC            Topic: NIDA

    PROJECT SUMMARY/ABSTRACT Nearly 4.4 million individuals are on community supervision in the United States, with the majority (about 80%) being supervised under probation.1 Justice involved persons (JIPs) have a 474% increased lifetime experience with heroin, a 303% increased use of OxyContin in the last 12 months, and a 256% increased use in pain medication in the last 12 months, compared to the g ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Glycan biomarker panels in liquid biopsies for predicting treatment response in lupus nephritis

    SBC: GLYCOPATH INC            Topic: 400

    Lupus nephritis (LN), an immune complex-mediated glomerulonephritis, affects up to two-thirds of patients with systemic lupus erythematosus. Despite standard treatment protocols, progression of the most aggressive forms of LN (class III and IV) to end-stage renal failure remains high. Thus, there is a need for biomarkers of therapeutic response that would allow physicians to make better-informed t ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Developing natural compound emodin as a therapy for alcoholic cardiomyopathy

    SBC: AcePre, LLC            Topic: NIAAA

    Project Summary: Alcoholic Cardiomyopathy (ACM) is the most prevalent form of ethanol-induced heart damage. Alcohol dose-dependently induces ACM, characterized by progressive reduction in myocardial contractility and ventricular dilatation, culminating in heart failure. At the cellular level, chronic alcohol consumption results in cardiomyocyte death, cardiac inflammation, and cardiac fibrosis. Th ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development

    SBC: FIBROTHERAPEUTICS INC            Topic: NHLBI

    Abstract Our long-term objective is to fill the unmet need for treatments for heart failure (HF). Caveolin-1 is a promising therapeutic target in fibrotic diseases. The profibrotic effects of caveolin-1 deficiency in cells and in mouse models is suppressed by a peptide equivalent to its active site (caveolin-1 scaffolding domain, CSD). We have shown the beneficial effects of CSD in two independent ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis

    SBC: FibroBiologics, LLC            Topic: NHLBI

    Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a median survival of only 3 - 5 years from diagnosis. Although two FDA-approved drugs, pirfenidone and nintedanib, may slow the rate of decline of lung function in some IPF patients, neither drug significantly alters the course of this lethal disease. There is a great need for new drugs with greater efficacy and le ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Developing novel LOX inhibitors to target chemotherapy resistant TNBC

    SBC: LOXIGEN, INC.            Topic: 102

    PROJECT SUMMARY Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype. It accounts for ~15% of all breast cancer yet is responsible for 30% of breast cancer deaths. TNBC is treated primarily by conventional chemotherapy; however, resistance to therapy is common, leading to high mortality rates. Importantly, the benefit of current therapeutic strategies used in chemoresi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government